News

Professor Hertzberg has made significant contributions during his ALLG membership to blood cancer research through the continued leadership of clinical trials across disease groups, the fostering of international collaborations and the mentoring of early career clinician researchers.

Professor Mark Hertzberg currently holds the position of Professor of Clinical Haematology at the Prince of Wales Hospital and University of New South Wales in Sydney. During his involvement with the ALLG, Professor Hertzberg has led a number of significant clinical trials and was Chair of the ALLG Scientific Advisory Committee from 2010 – 2017, overseeing the research direction and conduct of clinical trials across Australasia for patients with blood cancer.

Professor Hertzberg is currently Chief Investigator of the ALLG HD10 clinical trial into advanced stage Hodgkin lymphoma, a global collaboration led by the German Hodgkin Study Group (GHSG). The HD10 trial aimed to reduce the toxicity and side effects associated with combination chemotherapy and the duration of therapy for patients with Hodgkin disease. The analysis of this study, at just under three and a half years, confirmed that 95 percent of patients remain free of disease recurrence. With superior survival results, minimal side-effects and no known impact on fertility, the HD10 trial sets a new benchmark for the primary cure rate in this disease and will change how Hodgkin Lymphoma is treated worldwide.

Congratulations to Professor Hertzberg on his appointment to the ALLG Board of Directors.